コンパニオン診断の世界市場：市場規模、シェア、動向分析、機会、予測 - 製品・サービス別、技術別、適応症別、エンドユーザー別、地域別（2019年～2029年）

世界のコンパニオン診断の市場規模は、2022年に61億2,000万米ドルとなり、2029年には135億7,000万米ドルに達し、2023年～2029年の予測期間中にCAGRで12.15%の成長が予測されています。

世界市場は、医薬品と診断技術の共同開発、医薬品副作用の急増、個別化治療へのニーズの高まりにより、活況を呈しています。

当レポートでは、世界のコンパニオン診断市場について調査し、市場の洞察、市場概要、地域別の市場分析、競合情勢、企業プロファイル等に関する情報を提供しています。

目次

第1章 調査の枠組み

第2章 エグゼクティブサマリー

第3章 世界のコンパニオン診断市場の洞察

• 産業バリューチェーン分析
• DROC分析
  • 促進要因
    • 医薬品副作用の増加
    • 医薬品と診断技術の共同開発
  • 抑制要因
    • 医薬品開発および関連する臨床試験の高コスト
  • 機会
    • 次世代シーケンシングに対する需要の高まり
  • 課題
    • 多くの国における償還の課題
• 技術の進歩/最近の開発
• 規制の枠組み
• ポーターのファイブフォース分析
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入者の脅威
  • 代替品の脅威
  • 競合の激しさ

第4章 世界のコンパニオン診断の市場概要

• 市場規模・予測、2019年～2029年
  • 金額別（10億米ドル）
• 市場シェア・予測
  • 製品・サービス別
    • アッセイ、キット・試薬
    • ソフトウェア・サービス
  • 技術別
    • ポリメラーゼ連鎖反応
    • 次世代シーケンシング
    • In situハイブリダイゼーション
    • 免疫組織化学
    • その他
  • 適応症別
    • がん
    • 神経疾患
    • 心血管疾患
    • 感染症
    • その他
  • エンドユーザー別
    • 医薬品・バイオ医薬品
    • リファレンスラボラトリー
    • 受託研究機関
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ

第5章 北米のコンパニオン診断市場

• 市場規模・予測、2019年～2029年
  • 金額別（10億米ドル）
• 市場シェア・予測
  • 製品・サービス別
  • 技術別
  • 適応症別
  • エンドユーザー別
  • 国別
    • 米国
    • カナダ

第6章 欧州のコンパニオン診断市場

• 市場規模・予測、2019年～2029年
  • 金額別（10億米ドル）
• 市場シェア・予測
  • 製品・サービス別
  • 技術別
  • 適応症別
  • エンドユーザー別
  • 国別
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • オランダ
    • その他の欧州

第7章 アジア太平洋のコンパニオン診断市場

• 市場規模・予測、2019年～2029年
  • 金額別（10億米ドル）
• 市場シェア・予測
  • 製品・サービス別
  • 技術別
  • 適応症別
  • エンドユーザー別
  • 国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア・ニュージーランド
    • インドネシア
    • マレーシア
    • シンガポール
    • フィリピン
    • ベトナム
    • その他のアジア太平洋

第8章 ラテンアメリカのコンパニオン診断市場

• 市場規模・予測、2019年～2029年
  • 金額別（10億米ドル）
• 市場シェア・予測
  • 製品・サービス別
  • 技術別
  • 適応症別
  • エンドユーザー別
  • 国別
    • ブラジル
    • メキシコ
    • アルゼンチン
    • ペルー
    • その他のラテンアメリカ

第9章 中東・アフリカのコンパニオン診断市場

• 市場規模・予測、2019年～2029年
  • 金額別（10億米ドル）
• 市場シェア・予測
  • 製品・サービス別
  • 技術別
  • 適応症別
  • エンドユーザー別
  • 国別
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • クウェート
    • 南アフリカ
    • ナイジェリア
    • アルジェリア
    • その他の中東・アフリカ

第10章 競合情勢

• 主要企業と製品リスト
• 世界のコンパニオン診断企業の市場シェア分析、2022年
• 競合ベンチマーキング：運用パラメータ別
• 主要な戦略的開発（合併、買収、パートナーシップ等）

第11章 世界のコンパニオン診断市場におけるCOVID-19の影響

第12章 企業プロファイル（企業概要、財務マトリックス、競合情勢、主要な人材、主要な競合企業、連絡先、戦略的展望、SWOT分析）

• Abbott Laboratories Inc.
• Agilent Technologies Inc.
• F. Hoffmann-La Roche Ltd
• Biomerieux SA
• Qiagen NV
• Siemens Healthcare
• Thermo Fisher Scientific Inc.
• Danaher Corporation（Beckman Coulter Inc.）
• Almac Group
• Illumina Inc.
• Myriad Genetics Inc.
• Sysmex Corporation
• Abnova Corporation
• Guardant Health Inc
• その他の有力企業

第13章 主要な戦略的推奨事項

第14章 調査手法

Global Companion Diagnostics Market Size More Than Doubles to Touch USD 13.6 billion by 2029.

Global companion diagnostics market is flourishing because rising co-development of drug and diagnostic technology, surging incidences of adverse drug reactions, and increasing need for personalized treatment.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global companion diagnostics market size at USD 6.12 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global companion diagnostics market size to grow at a significant CAGR of 12.15% reaching a value of USD 13.57 billion by 2029. Major growth factors of global companion diagnostics market include increasing requirement for personalized treatment, broad application areas of companion diagnostics, surging demand for focused therapy, growing cancer occurrences, and development of new biomarkers for various illnesses. Personalized medicine is becoming increasingly popular as the field of genetics and genetic engineering expands fast. It is now possible to provide the correct medicine to the right individual at the right time based on a person's genetic features. As part of a patient-centric drug development approach, many pharmaceutical and biopharmaceutical companies are developing targeted medication therapies. Numerous third-party companion diagnostic services provide similar services to enterprises that face a greater financial strain. As a result, the issue of high startup expenses has been effectively handled. These reasons are projected to drive the companion diagnostics market during the forecast period. However, increasing expense of drug development and associated clinical trials during the period in analysis.

Global Companion Diagnostics Market - Overview:

A companion diagnostics device is a medical gadget that is used in conjunction with therapeutic medications to assess the effect and applicability of drugs on a specific human body. Companion diagnostics are developed in tandem with medications to select or exclude patient groups based on the features to which they respond to therapy. This device assists the healthcare provider in determining whether a specific treatment is beneficial to the patient. In 2020, Roche gained FDA approval for Cobas EGFR Mutation Test v2 companion diagnostic for EGFR tyrosine kinase inhibitor for lung cancer treatment. Companion Diagnostic (CDx) is a clinical test created in collaboration with a therapeutic medicine to identify responders and non-responders to that therapy. It is done to determine which patient groups may and cannot be treated with the relevant medicine. CDx assists practitioners in determining the benefits, side effects, and hazards connected with therapeutic drug intake, guaranteeing patient safety. Growing patient preferences for customized therapy, expanding applications of personalized medications, increased prevalence of chronic diseases, and rising occurrences of allergies in patients as a result of medication adverse effects all contribute to the development of customized CDx, propelling the global Companion Diagnostics Market forward. Furthermore, CDx tests' features, such as cost-effectiveness, high sensitivity, and rapid and precise results in short timeframes, aid in the expansion of the companion diagnostics market.

Impact of COVID-19 on Global Companion Diagnostics Market

COVID-19 had a detrimental impact on the companion diagnostics market. In addition, prominent market participants witnessed a considerable drop in income owing to a fall in testing volume and other variables. In terms of sales, the market grew by 15.1% in 2020, compared to 19.8% in 2019. Revenue generated by the major players decreased significantly in 2020. However, the lifting of lockdown restrictions, stay-at-home orders in many nations, the introduction of novel diagnostic tests, and the re-establishment of the supply chain network were major contributors in the recovery of testing in 2021. As a result, the restart of cancer diagnostics testing, and the introduction of novel diagnostic tests boosted demand in 2021.

Global Companion Diagnostics Market - By Indication:

Based on indication, global companion diagnostics market is divided into Cancer, Neurological Disorders, Cardiovascular Diseases, and Infectious Diseases. In 2022, the cancer segment held the highest market share. Increased cancer prevalence, an increase in the number of cancer R&D activities, an increase in the number of unmet needs for cancer treatment, an increase in the number of FDA-approved companion diagnostics, and increased patient awareness about personalized medicine are some of the key factors driving the growth of the oncology segment. The cancer segment includes lung cancer, breast cancer, blood cancer, and colorectal cancer. Amongst them, lung cancer holds the highest market share. Companion diagnostic tests (CDXs) are regarded mandatory in the decision-making process for lung cancer treatment with targeted treatments. Individuals with lung cancer who undergo companion diagnostics as part of their initial treatment have a higher chance of surviving than those who do not. Globally, the increasing incidence rate of non-small cell lung cancer (NSCLC), combined with an increase in the development of oncology companion diagnostic tests for the disease, is likely to drive sector growth.

Competitive Landscape:

Major players operating in global companion diagnostics market include: Abbott Laboratories Inc., Agilent Technologies Inc., F. Hoffmann-La Roche Ltd, Biomerieux SA, Qiagen NV, Siemens Healthcare, Thermo Fisher Scientific Inc., Danaher Corporation (Beckman Coulter Inc.), Almac Group, Illumina Inc., Myriad Genetics Inc., Sysmex Corporation, Abnova Corporation, and Guardant Health Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Companion Diagnostics Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Companion Diagnostics Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

2. Executive Summary

3. Global Companion Diagnostics Market Insights

• 3.1. Industry Value Chain Analysis
• 3.2. DROC Analysis
  • 3.2.1. Growth Drivers
    • 3.2.1.1. Increasing Cases of Adverse Drug Reactions
    • 3.2.1.2. Co-development of Drug and Diagnostic Technology
  • 3.2.2. Restraints
    • 3.2.2.1. High Cost of Drug Development and Associated Clinical Trials
  • 3.2.3. Opportunities
    • 3.2.3.1. Rising Demand for Next Generation Sequencing
  • 3.2.4. Challenges
    • 3.2.4.1. Reimbursement Issues Among Many Countries
• 3.3. Technology Advancements/Recent Developments
• 3.4. Regulatory Framework
• 3.5. Porter's Five Forces Analysis
  • 3.5.1. Bargaining Power of Suppliers
  • 3.5.2. Bargaining Power of Buyers
  • 3.5.3. Threat of New Entrants
  • 3.5.4. Threat of Substitutes
  • 3.5.5. Intensity of Rivalry

4. Global Companion Diagnostics Market Overview

• 4.1. Market Size & Forecast, 2019-2029
  • 4.1.1. By Value (USD Billion)
• 4.2. Market Share & Forecast
  • 4.2.1. By Product & Service
    • 4.2.1.1. Assays, Kits & Reagents
    • 4.2.1.2. Software & Services
  • 4.2.2. By Technology
    • 4.2.2.1. Polymerase Chain Reaction
    • 4.2.2.2. Next-generation Sequencing
    • 4.2.2.3. In Situ Hybridization
    • 4.2.2.4. Immunohistochemistry
    • 4.2.2.5. Others
  • 4.2.3. By Indication
    • 4.2.3.1. Cancer
    • 4.2.3.1.1. Lung Cancer
    • 4.2.3.1.2. Breast Cancer
    • 4.2.3.1.3. Blood Cancer
    • 4.2.3.1.4. Colorectal Cancer
    • 4.2.3.1.5. Others
    • 4.2.3.2. Neurological Disorders
    • 4.2.3.3. Cardiovascular Diseases
    • 4.2.3.4. Infectious Diseases
    • 4.2.3.5. Others
  • 4.2.4. By End User
    • 4.2.4.1. Pharmaceutical & Biopharmaceutical
    • 4.2.4.2. Reference Laboratories
    • 4.2.4.3. Contract Research Organizations
    • 4.2.4.4. Others
  • 4.2.5. By Region
    • 4.2.5.1. North America
    • 4.2.5.2. Europe
    • 4.2.5.3. Asia Pacific (APAC)
    • 4.2.5.4. Latin America (LATAM)
    • 4.2.5.5. Middle East and Africa (MEA)

5. North America Companion Diagnostics Market

• 5.1. Market Size & Forecast, 2019-2029
  • 5.1.1. By Value (USD Billion)
• 5.2. Market Share & Forecast
  • 5.2.1. By Product & Service
  • 5.2.2. By Technology
  • 5.2.3. By Indication
  • 5.2.4. By End User
  • 5.2.5. By Country
    • 5.2.5.1. US
    • 5.2.5.1.1. By Product & Service
    • 5.2.5.1.2. By Technology
    • 5.2.5.1.3. By Indication
    • 5.2.5.1.4. By End User
    • 5.2.5.2. Canada
    • 5.2.5.2.1. By Product & Service
    • 5.2.5.2.2. By Technology
    • 5.2.5.2.3. By Indication
    • 5.2.5.2.4. By End User

6. Europe Companion Diagnostics Market

• 6.1. Market Size & Forecast, 2019-2029
  • 6.1.1. By Value (USD Billion)
• 6.2. Market Share & Forecast
  • 6.2.1. By Product & Service
  • 6.2.2. By Technology
  • 6.2.3. By Indication
  • 6.2.4. By End User
  • 6.2.5. By Country
    • 6.2.5.1. Germany
    • 6.2.5.1.1. By Product & Service
    • 6.2.5.1.2. By Technology
    • 6.2.5.1.3. By Indication
    • 6.2.5.1.4. By End User
    • 6.2.5.2. UK
    • 6.2.5.2.1. By Product & Service
    • 6.2.5.2.2. By Technology
    • 6.2.5.2.3. By Indication
    • 6.2.5.2.4. By End User
    • 6.2.5.3. Italy
    • 6.2.5.3.1. By Product & Service
    • 6.2.5.3.2. By Technology
    • 6.2.5.3.3. By Indication
    • 6.2.5.3.4. By End User
    • 6.2.5.4. France
    • 6.2.5.4.1. By Product & Service
    • 6.2.5.4.2. By Technology
    • 6.2.5.4.3. By Indication
    • 6.2.5.4.4. By End User
    • 6.2.5.5. Spain
    • 6.2.5.5.1. By Product & Service
    • 6.2.5.5.2. By Technology
    • 6.2.5.5.3. By Indication
    • 6.2.5.5.4. By End User
    • 6.2.5.6. The Netherlands
    • 6.2.5.6.1. By Product & Service
    • 6.2.5.6.2. By Technology
    • 6.2.5.6.3. By Indication
    • 6.2.5.6.4. By End User
    • 6.2.5.7. Rest of Europe
    • 6.2.5.7.1. By Product & Service
    • 6.2.5.7.2. By Technology
    • 6.2.5.7.3. By Indication
    • 6.2.5.7.4. By End User

7. Asia-Pacific Companion Diagnostics Market

• 7.1. Market Size & Forecast, 2019-2029
  • 7.1.1. By Value (USD Billion)
• 7.2. Market Share & Forecast
  • 7.2.1. By Product & Service
  • 7.2.2. By Technology
  • 7.2.3. By Indication
  • 7.2.4. By End User
  • 7.2.5. By Country
    • 7.2.5.1. China
    • 7.2.5.1.1. By Product & Service
    • 7.2.5.1.2. By Technology
    • 7.2.5.1.3. By Indication
    • 7.2.5.1.4. By End User
    • 7.2.5.2. India
    • 7.2.5.2.1. By Product & Service
    • 7.2.5.2.2. By Technology
    • 7.2.5.2.3. By Indication
    • 7.2.5.2.4. By End User
    • 7.2.5.3. Japan
    • 7.2.5.3.1. By Product & Service
    • 7.2.5.3.2. By Technology
    • 7.2.5.3.3. By Indication
    • 7.2.5.3.4. By End User
    • 7.2.5.4. South Korea
    • 7.2.5.4.1. By Product & Service
    • 7.2.5.4.2. By Technology
    • 7.2.5.4.3. By Indication
    • 7.2.5.4.4. By End User
    • 7.2.5.5. Australia & New Zealand
    • 7.2.5.5.1. By Product & Service
    • 7.2.5.5.2. By Technology
    • 7.2.5.5.3. By Indication
    • 7.2.5.5.4. By End User
    • 7.2.5.6. Indonesia
    • 7.2.5.6.1. By Product & Service
    • 7.2.5.6.2. By Technology
    • 7.2.5.6.3. By Indication
    • 7.2.5.6.4. By End User
    • 7.2.5.7. Malaysia
    • 7.2.5.7.1. By Product & Service
    • 7.2.5.7.2. By Technology
    • 7.2.5.7.3. By Indication
    • 7.2.5.7.4. By End User
    • 7.2.5.8. Singapore
    • 7.2.5.8.1. By Product & Service
    • 7.2.5.8.2. By Technology
    • 7.2.5.8.3. By Indication
    • 7.2.5.8.4. By End User
    • 7.2.5.9. Philippines
    • 7.2.5.9.1. By Product & Service
    • 7.2.5.9.2. By Technology
    • 7.2.5.9.3. By Indication
    • 7.2.5.9.4. By End User
    • 7.2.5.10. Vietnam
    • 7.2.5.10.1. By Product & Service
    • 7.2.5.10.2. By Technology
    • 7.2.5.10.3. By Indication
    • 7.2.5.10.4. By End User
    • 7.2.5.11. Rest of APAC
    • 7.2.5.11.1. By Product & Service
    • 7.2.5.11.2. By Technology
    • 7.2.5.11.3. By Indication
    • 7.2.5.11.4. By End User

8. Latin America Companion Diagnostics Market

• 8.1. Market Size & Forecast, 2019-2029
  • 8.1.1. By Value (USD Billion)
• 8.2. Market Share & Forecast
  • 8.2.1. By Product & Service
  • 8.2.2. By Technology
  • 8.2.3. By Indication
  • 8.2.4. By End User
  • 8.2.5. By Country
    • 8.2.5.1. Brazil
    • 8.2.5.1.1. By Product & Service
    • 8.2.5.1.2. By Technology
    • 8.2.5.1.3. By Indication
    • 8.2.5.1.4. By End User
    • 8.2.5.2. Mexico
    • 8.2.5.2.1. By Product & Service
    • 8.2.5.2.2. By Technology
    • 8.2.5.2.3. By Indication
    • 8.2.5.2.4. By End User
    • 8.2.5.3. Argentina
    • 8.2.5.3.1. By Product & Service
    • 8.2.5.3.2. By Technology
    • 8.2.5.3.3. By Indication
    • 8.2.5.3.4. By End User
    • 8.2.5.4. Peru
    • 8.2.5.4.1. By Product & Service
    • 8.2.5.4.2. By Technology
    • 8.2.5.4.3. By Indication
    • 8.2.5.4.4. By End User
    • 8.2.5.5. Rest of LATAM
    • 8.2.5.5.1. By Product & Service
    • 8.2.5.5.2. By Technology
    • 8.2.5.5.3. By Indication
    • 8.2.5.5.4. By End User

9. Middle East & Africa Companion Diagnostics Market

• 9.1. Market Size & Forecast, 2019-2029
  • 9.1.1. By Value (USD Billion)
• 9.2. Market Share & Forecast
  • 9.2.1. By Product & Service
  • 9.2.2. By Technology
  • 9.2.3. By Indication
  • 9.2.4. By End User
  • 9.2.5. By Country
    • 9.2.5.1. Saudi Arabia
    • 9.2.5.1.1. By Product & Service
    • 9.2.5.1.2. By Technology
    • 9.2.5.1.3. By Indication
    • 9.2.5.1.4. By End User
    • 9.2.5.2. UAE
    • 9.2.5.2.1. By Product & Service
    • 9.2.5.2.2. By Technology
    • 9.2.5.2.3. By Indication
    • 9.2.5.2.4. By End User
    • 9.2.5.3. Qatar
    • 9.2.5.3.1. By Product & Service
    • 9.2.5.3.2. By Technology
    • 9.2.5.3.3. By Indication
    • 9.2.5.3.4. By End User
    • 9.2.5.4. Kuwait
    • 9.2.5.4.1. By Product & Service
    • 9.2.5.4.2. By Technology
    • 9.2.5.4.3. By Indication
    • 9.2.5.4.4. By End User
    • 9.2.5.5. South Africa
    • 9.2.5.5.1. By Product & Service
    • 9.2.5.5.2. By Technology
    • 9.2.5.5.3. By Indication
    • 9.2.5.5.4. By End User
    • 9.2.5.6. Nigeria
    • 9.2.5.6.1. By Product & Service
    • 9.2.5.6.2. By Technology
    • 9.2.5.6.3. By Indication
    • 9.2.5.6.4. By End User
    • 9.2.5.7. Algeria
    • 9.2.5.7.1. By Product & Service
    • 9.2.5.7.2. By Technology
    • 9.2.5.7.3. By Indication
    • 9.2.5.7.4. By End User
    • 9.2.5.8. Rest of MEA
    • 9.2.5.8.1. By Product & Service
    • 9.2.5.8.2. By Technology
    • 9.2.5.8.3. By Indication
    • 9.2.5.8.4. By End User

10. Competitive Landscape

• 10.1. List of Key Players and Their Offerings
• 10.2. Global Companion Diagnostics Company Market Share Analysis, 2022
• 10.3. Competitive Benchmarking, By Operating Parameters
• 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Companion Diagnostics Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

• 12.1. Abbott Laboratories Inc.
• 12.2. Agilent Technologies Inc.
• 12.3. F. Hoffmann-La Roche Ltd
• 12.4. Biomerieux SA
• 12.5. Qiagen NV
• 12.6. Siemens Healthcare
• 12.7. Thermo Fisher Scientific Inc.
• 12.8. Danaher Corporation (Beckman Coulter Inc.)
• 12.9. Almac Group
• 12.10. Illumina Inc.
• 12.11. Myriad Genetics Inc.
• 12.12. Sysmex Corporation
• 12.13. Abnova Corporation
• 12.14. Guardant Health Inc
• 12.15. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

• 14.1. Qualitative Research
  • 14.1.1. Primary & Secondary Research
• 14.2. Quantitative Research
• 14.3. Market Breakdown & Data Triangulation
  • 14.3.1. Secondary Research
  • 14.3.2. Primary Research
• 14.4. Breakdown of Primary Research Respondents, By Region
• 14.5. Assumptions & Limitations